Twist Bioscience (NASDAQ:TWST) Posts Earnings Results, Beats Expectations By $0.05 EPS

Twist Bioscience (NASDAQ:TWST - Get Free Report) announced its earnings results on Thursday. The company reported ($0.79) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.84) by $0.05, Briefing.com reports. The firm had revenue of $75.30 million for the quarter, compared to analyst estimates of $70.70 million. Twist Bioscience had a negative return on equity of 32.16% and a negative net margin of 78.44%. The business's revenue was up 25.1% on a year-over-year basis. During the same quarter last year, the firm posted ($1.06) EPS.

Twist Bioscience Stock Up 28.7 %

NASDAQ:TWST traded up $9.20 on Friday, reaching $41.21. The company's stock had a trading volume of 4,457,624 shares, compared to its average volume of 975,484. The firm has a market cap of $2.38 billion, a price-to-earnings ratio of -11.42 and a beta of 1.64. Twist Bioscience has a 12-month low of $11.81 and a 12-month high of $43.21. The stock has a 50 day moving average price of $34.03 and a 200 day moving average price of $30.96.

Analyst Ratings Changes

Several analysts have recently issued reports on TWST shares. Barclays lifted their target price on shares of Twist Bioscience from $40.00 to $45.00 and gave the company an "overweight" rating in a research report on Friday. The Goldman Sachs Group upgraded Twist Bioscience from a "neutral" rating to a "buy" rating and raised their target price for the company from $25.00 to $45.00 in a research report on Wednesday, January 17th. Robert W. Baird lifted their price target on Twist Bioscience from $39.00 to $40.00 and gave the stock an "outperform" rating in a research note on Friday. Evercore ISI increased their price objective on shares of Twist Bioscience from $46.00 to $50.00 and gave the company an "outperform" rating in a report on Friday. Finally, Scotiabank boosted their price objective on Twist Bioscience from $30.00 to $43.00 and gave the stock a "sector outperform" rating in a research note on Monday, February 5th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $41.67.

Insider Activity at Twist Bioscience

In other news, CEO Emily M. Leproust sold 1,128 shares of the company's stock in a transaction that occurred on Wednesday, March 20th. The shares were sold at an average price of $33.52, for a total value of $37,810.56. Following the transaction, the chief executive officer now directly owns 515,281 shares in the company, valued at approximately $17,272,219.12. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, CEO Emily M. Leproust sold 1,128 shares of the business's stock in a transaction on Wednesday, March 20th. The stock was sold at an average price of $33.52, for a total value of $37,810.56. Following the sale, the chief executive officer now owns 515,281 shares in the company, valued at approximately $17,272,219.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Robert Chess sold 4,110 shares of the firm's stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $34.98, for a total value of $143,767.80. Following the transaction, the director now owns 64,169 shares of the company's stock, valued at $2,244,631.62. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 13,211 shares of company stock worth $449,573. Company insiders own 3.92% of the company's stock.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.